An Australasian and French Phase III, Multicentre, Randomised Trial Comparing Lenalidomide Consolidation versus No Consolidation in Patients With Chronic Lymphocytic Leukaemia and Residual Disease Following Induction Chemotherapy (CLL6)

DOI number 10.58109/f484-cr34
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

David Gottlieb (Westmead Hospital)
Date Made Available 2026
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

This dataset includes data for CLL06 trial participants with 192 participants withThis dataset contains individual participant data (IPD) from the CLL6 study, a phase III randomised trial evaluating lenalidomide consolidation versus no consolidation in patients with chronic lymphocytic leukaemia (CLL) with residual disease following induction chemotherapy.

Participants were recruited at sites in, Australia wide). The study commenced in 2011 and conducted the last patient last visit in 2018
This dataset is suitable for secondary analyses including evaluation of consolidation strategies, disease response, long-term outcomes, and optimisation of treatment approaches in CLL.
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Oncology and Carcinogenesis
ANZCTR Reference ACTRN12610000060044
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
MM16
CML10